Adenosine A2A Receptor AntagonistNDC: 42747002030 (20mg) / 42747004030 (40mg)

Istradefylline (Nourianz): Cost, CMS NADAC & Insurance Coverage

What it's for: Non-dopaminergic once-daily oral add-on therapy to levodopa/carbidopa that targets adenosine A2A receptors in the basal ganglia to reduce daily 'OFF' time. (Source: FDA Prescribing Information (NDA 022075) & Michael J. Fox Foundation)

30-Day Retail Cash Range
$1,680 – $1,950 / 30 days (30 tablets)
Source: Specialty Pharmacy Published Cash & WAC Benchmarks (Oct 2026)
CMS NADAC Baseline (As of 2026-10-28)
Not published in CMS Retail NADAC
Per unit: Not published in Retail NADAC
2026 Medicare Part D Patient Cost
25%–33% Specialty coinsurance up to the $2,100 annual Part D cap (if on formulary or exception approved)
Tier 5 (Specialty Tier) or Non-Formulary (requires Formulary Exception on many plans)
1. Published Prices(Cash & Medicare)2. Plan-Adjusted(Payer MRF Rate)3. Verified Price(Real-Time 270/271 Check)

Accuracy Level — Tier 1 Published Prices: You are currently viewing general published hospital cash prices, Medicare baselines, and multi-payer ranges. Add your insurance card to unlock Tier 2 plan pricing and Tier 3 verified benefit checks.

Cost Across Insurances Matrix for Istradefylline

Tier 1: General Published Rates Across 9 InsurancesEvery cell labeled with official Source + Date • “Not published” shown honestly where proprietary

Hospital procedure cells are extracted from 14 Bay Area hospital MRFs (45 CFR § 180.50, Oct 2026); medication cells use CMS NADAC (as of 2026-10-28) & CY 2026 Medicare Part D / Medi-Cal Rx rules.

Parkinson's Service / Medication
Self-Pay / Cash Price
Hospital MRF / Retail Cash
Medicare Rate
2026 CMS / NADAC / Part D
Anthem Blue Cross
MRF Negotiated / Formulary
Blue Shield of CA
MRF Negotiated / Formulary
UnitedHealthcare
MRF Negotiated / Formulary
Aetna
MRF Negotiated / Formulary
Cigna
MRF Negotiated / Formulary
Kaiser Permanente
MRF Negotiated / Formulary
Medi-Cal (CA Medicaid)
CA DHCS / Medi-Cal Rx
MedicationSpecialty / DME (42747002030)
Istradefylline (Nourianz)
$1,680 – $1,950 / 30 days (30 tablets)

$1,680 – $1,950 / 30 days (30 tablets)

Source: Specialty Pharmacy Published Cash & WAC Benchmarks (Oct 2026)
Date: Oct 2026
Not published

Not published in CMS Retail NADAC (Limited-Distribution Specialty Pharmacy) • Medicare Part D patient cost: 25%–33% Specialty coinsurance up to the $2,100 annual Part D cap (if on formulary or exception approved)

Source: CMS NADAC 2026 (data.medicaid.gov Dataset fbb83258-11c7-47f5-8b18-5f8e79f7e704 — Verified absent from retail survey) & CMS CY 2026 Medicare Part D Public Formulary File (Oct 2026)
Date: 2026-10-28
Not published

Tier 4/Specialty; Prior Authorization + Step Therapy required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.

Source: Anthem Blue Cross 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021)
Date: Oct 2026
Not published

Tier 4/Specialty; Prior Authorization + Step Therapy required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.

Source: Blue Shield of CA 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021)
Date: Oct 2026
Not published

Excluded or Specialty Tier with Prior Authorization + Step Therapy. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.

Source: UnitedHealthcare 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021)
Date: Oct 2026
Not published

Non-Preferred Brand / Specialty; Prior Authorization + Step Therapy required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.

Source: Aetna 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021)
Date: Oct 2026
Not published

Tier 4/Specialty; Prior Authorization + Step Therapy required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.

Source: Cigna 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021)
Date: Oct 2026
Not published

Non-Formulary (requires specialty formulary exception). Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.

Source: Kaiser Permanente 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021)
Date: Oct 2026
$0 patient copay

$0 copay ONLY with approved Medi-Cal Rx Prior Authorization.

Source: CA DHCS Medi-Cal Rx Contract Drug List (CDL) & PA Policy
Date: Oct 2026
Official CMS NADAC Acquisition Cost Baseline

National Average Drug Acquisition Cost (NADAC)

Published Status: Not published in CMS Retail NADAC (Specialty / Part B DME distribution)
NDC & Description: 42747002030 (20mg) / 42747004030 (40mg) — Not published in CMS Retail NADAC (Limited-Distribution Specialty Pharmacy)
NADAC Per-Unit Rate: Not published in Retail NADAC
Typical 30-Day Regimen (20 mg or 40 mg tablet once daily (30 tablets / 30-day supply)): Not published in CMS Retail NADAC
Effective Date / As-of Date: Effective 2026-10-21 (Verified as of 2026-10-28)
Source: CMS NADAC 2026 (data.medicaid.gov Dataset fbb83258-11c7-47f5-8b18-5f8e79f7e704 — Verified absent from retail survey)
CY 2026 Medicare Part D Formulary Rules

Medicare Part D Tier, Prior Auth & $2,100 Cap

Formulary Tier: Tier 5 (Specialty Tier) or Non-Formulary (requires Formulary Exception on many plans)
Prior Authorization: Yes — requires documented 'OFF' episodes on carbidopa/levodopa AND failure/intolerance of at least two generic adjunctive classes (dopamine agonist, MAO-B inhibitor, COMT inhibitor)
Step Therapy: Yes (2+ generic adjunctive classes)
Quantity Limits: 30 tablets per 30 days
2026 Patient Out-of-Pocket: 25%–33% Specialty coinsurance up to the $2,100 annual Part D cap (if on formulary or exception approved)
Source: CMS CY 2026 Medicare Part D Public Formulary File (Oct 2026)
California Commercial Payers & Medi-Cal Rx

Payer-by-Payer Formulary & Prior Authorization Notes

View Prior Auth Documentation Checklist →
Anthem Blue Cross

Tier 4/Specialty; Prior Authorization + Step Therapy required.

Blue Shield of California

Tier 4/Specialty; Prior Authorization + Step Therapy required.

UnitedHealthcare (UHC)

Excluded or Specialty Tier with Prior Authorization + Step Therapy.

Aetna

Non-Preferred Brand / Specialty; Prior Authorization + Step Therapy required.

Cigna

Tier 4/Specialty; Prior Authorization + Step Therapy required.

Kaiser Permanente

Non-Formulary (requires specialty formulary exception).

Medi-Cal Rx (CA Medicaid)

$0 copay ONLY with approved Medi-Cal Rx Prior Authorization.